Tel Aviv Hospital treats 29 of the 30 Kovid-19 patients a day, the oil said.



Of the 30 moderate to severe CVD-19 patients treated by Tel Aviv Saursky Medical Center (Ichilov H Hospital Spital), 29 recovered and only three were discharged from the hospital. For five days, the hospital said Friday.

The 30-year-old patient also recovered but it took longer.

Patients Pro. Nadir Arbor was given the Exo-CD24 Covid-19 treatment, which is based on the CD24-rich Exosomes and is intended to combat the cytokine storm that is associated with many COVID-19 deaths worldwide.

A cytokine storm is when the immune system essentially goes into overdrive and begins to attack healthy cells. Exoso is responsible for cell-to-cell communication. In this case, the exosomes deliver the CD24 protein to the lungs, which helps calm the immune system.

“These proteins are located on the surface of cells and play a well-known and important role in controlling the immune system,” said Dr. Shiran Shapira, who works in Arbor’s lab.

Arbor has been researching exosomes for the better part of two decades. He said it was about six months since the idea to use the treatment in the fight against COVID-19 emerged, until it was first tested in humans.

The treatment is inhaled once a day for a few times for five days. Arber explains that it directly targets the lungs, the site of the storm, as opposed to other treatments that can be given systematically and therefore produce serious side effects.

Most patients who received exo-CD24 showed significant improvement in two days.

The hospital has appealed to the health ministry to proceed with further clinical trials. Once approved, treatment can be attempted on additional patients.Prof. Nadir Arbor (Credit: Ichilov Hospital)Prof. Nadir Arbor (Credit: Ichilov Hospital)

“This is an innovative treatment that can be produced quickly and efficiently at low and low cost,” Arber explained. “Even if the vaccines are supposed to do, and if no new mutations occur, one way or another, the coronavirus will stay with us.”

Sirsky’s head, Prof. Ronnie Gamzu called the treatment “innovative and sophisticated” and said the results of the first round of hearings “gave us all an expression of faith in the system.” He added that he would personally help Arbor to obtain the necessary approvals from the Ministry of Health to carry out the research.
Gazmu served as Israel’s coronavirus commissioner from August Gust to November 2020. “The international understanding is that vaccines as well as drugs need to be developed to treat the disease,” he said. “I am proud that Ichilov… perhaps blue and – a white solution to a terrible global epidemic,” he concluded.

This is not the first Israeli drug to promise treatment for Covid-19.

Last year, Hadasah-University Medical Center reported similar results from the use of the drug Aloisetra, by the company Anilivex. Developed on the basis of research by Darer Maverick. Like Exo-CD24, Alocetra is for the treatment of immune system hypertrophy. Still, Israel’s Puristem Therapeutics is investigating the use of its PLX-PAD placenta-based cellular therapy, which the company says it hopes will make a difference. Role in reducing the harmful effects of COVID-19 on tissues on the lungs. The company is now also engaged in clinical trials.